ofloxacin has been researched along with Infections, Legionella pneumophila in 38 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the safety and efficacy of a ten-day oral course of ofloxacin (400 mg 12 hourly) as compared with erythromycin (400 mg every 6 hours) for treatment of lower respiratory tract infections, fifty-two adult outpatients with pulmonary infiltrates (pneumonia) or with a cough and purulent sputum (bronchitis) were evaluated." | 5.07 | Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin. ( Hooton, TM; Lipsky, BA; Pecoraro, RE; Peugeot, RL, 1991) |
| " We diagnosed Legionnaires' pneumonia accompanied by clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS), and started treatment with ciprofloxacin and methylprednisolone at 1 mg/kg/day." | 3.77 | [A case of Legionnaires' pneumonia accompanied by clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) with transient altered mental status and cerebellar symptoms, which responded to treatment by antibiotics and corticoste ( Akazawa, K; Hibi, M; Hibino, M; Hikino, K; Oe, M, 2011) |
| "Levofloxacin may produce a faster clinical response than older macrolides, allowing for shorter hospital stay." | 2.71 | Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. ( Carratalà, J; Dorca, J; Fernández-Sabé, N; Gudiol, F; Manresa, F; Mykietiuk, A; Verdaguer, R, 2005) |
| "levofloxacin), patients were stratified by the severity of pneumonia." | 2.71 | Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. ( Alemany Francés, L; Blázquez Garrido, RM; Espinosa Parra, FJ; Huerta, FH; Ramos Guevara, RM; Sánchez-Nieto, JM; Segovia Hernández, M; Serrano Martínez, JA, 2005) |
| "Ofloxacin was administered orally in 32 cases (200 mg b." | 2.66 | [Treatment of pneumonia caused by Legionella, Mycoplasma, Chlamydiae and Rickettsia using ofloxacin]. ( Beuscart, C; Chidiac, C; Leroy, O; Mouton, Y; Senneville, E; Sivery, B; Vincent du Laurier, M, 1989) |
| "Clinical manifestations of Legionnaires' disease are not specific and current diagnostic scores are of limited use." | 2.46 | An update on Legionella. ( Carratalà, J; Garcia-Vidal, C, 2010) |
| "Amoxicillin was prescribed in 108 cases, fluoroquinolone in 24 cases, macrolide in 18 cases." | 1.36 | [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia]. ( Bernardin, G; Cua, E; de Salvador, F; Dellamonica, J; Hyvernat, H; Landraud, L; Risso, K; Roger, PM; Vassallo, M, 2010) |
| "An analysis of patients with Legionnaires' disease from the Community-Acquired Pneumonia Organization database was performed." | 1.36 | Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study. ( Arnold, F; Griffin, AT; Peyrani, P; Wiemken, T, 2010) |
| " These results, including in vitro antibacterial activity against clinical isolates and therapeutic efficacy of a humanized dosing regimen, provide good evidence to support the use of LVFX at 500 mg once a day for treating patient with legionnaires disease." | 1.35 | [Therapeutic efficacy of levofloxacin against a model of replicable Legionella pneumophila lung infection in DBA/2 mice]. ( Fujikawa, K; Karibe, Y; Kashimoto, Y; Kurosaka, Y; Namba, K; Otani, T; Uoyama, S; Yamaguchi, K, 2009) |
| "This report describes an outbreak of Legionnaires' disease in severely immunosuppressed patients hospitalised at a cancer centre." | 1.34 | Outbreak of Legionnaires' disease in immunosuppressed patients at a cancer centre: usefulness of universal urine antigen testing and early levofloxacin therapy. ( Angeles Domínguez, M; Carratalà, J; Fernández-Sevilla, A; Gudiol, C; Verdaguer, R, 2007) |
| "When treated with olamufloxacin (5 mg/kg given orally twice a day) for 7 days, 11 of 12 L." | 1.32 | In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ( Arakaki, N; Higa, F; Kawakami, K; Koide, M; Saito, A; Shinzato, T; Tateyama, M, 2003) |
| "Levofloxacin was efficacious at both 500 mg for 7 to 14 days and 750 mg for 5 days." | 1.32 | Levofloxacin efficacy in the treatment of community-acquired legionellosis. ( Greenberg, RN; Khashab, MM; Olson, WH; Stout, JE; Tennenberg, AM; Yu, VL; Zadeikis, N, 2004) |
| "We reported a case of fibrosing alveolitis following Legionella pneumonia." | 1.31 | [Fibrosing alveolitis following Legionella pneumonia]. ( Hatakeyama, S; Oka, T; Suzuki, K; Tachibana, A; Tateda, K; Yamaguchi, K, 2000) |
| " The terminal half-life phase of elimination from plasma was 1." | 1.31 | In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. ( Doyle, E; Edelstein, MA; Edelstein, PH; Shinzato, T, 2001) |
| "Levofloxacin (400 mg/day) was then given orally, in combination with injected imipenem/cilastatin." | 1.30 | [Legionella pneumonia successfully treated despite late diagnosis]. ( Takazakura, E; Tsuji, H, 1997) |
| "Levofloxacin was significantly more active than erythromycin, and as active as ofloxacin or ciprofloxacin in this assay." | 1.29 | In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ( Edelstein, MA; Edelstein, PH; Lehr, KH; Ren, J, 1996) |
| "Ofloxacin was evaluated as an antibiotic for possible use in the therapy of Legionnaires' disease in relation to its ability to penetrate alveolar phagocytes and inhibit Legionella pneumophila intracellular replication." | 1.27 | The effect of ofloxacin on the intracellular growth of Legionella pneumophila in guinea pig alveolar phagocytes. ( Baskerville, A; Featherstone, AS; Fitzgeorge, RB, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.26) | 18.7374 |
| 1990's | 9 (23.68) | 18.2507 |
| 2000's | 17 (44.74) | 29.6817 |
| 2010's | 10 (26.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carratalà, J | 3 |
| Garcia-Vidal, C | 1 |
| Kashimoto, Y | 1 |
| Kurosaka, Y | 1 |
| Karibe, Y | 1 |
| Uoyama, S | 1 |
| Fujikawa, K | 1 |
| Namba, K | 1 |
| Otani, T | 1 |
| Yamaguchi, K | 3 |
| Roger, PM | 1 |
| Risso, K | 1 |
| Hyvernat, H | 1 |
| Landraud, L | 1 |
| Vassallo, M | 1 |
| Dellamonica, J | 1 |
| de Salvador, F | 1 |
| Cua, E | 1 |
| Bernardin, G | 1 |
| Griffin, AT | 1 |
| Peyrani, P | 1 |
| Wiemken, T | 1 |
| Arnold, F | 1 |
| Han, JH | 1 |
| Nguyen, JC | 1 |
| Harada, S | 1 |
| Baddour, LM | 1 |
| Edelstein, PH | 4 |
| Rókusz, L | 1 |
| Sato, T | 1 |
| Tateda, K | 2 |
| Kimura, S | 1 |
| Ishii, Y | 1 |
| Rafat, C | 1 |
| Vimont, S | 1 |
| Ancel, PY | 1 |
| Xu-Dubois, YC | 1 |
| Mesnard, L | 1 |
| Ouali, N | 1 |
| Denis, M | 1 |
| Vandewalle, A | 1 |
| Rondeau, E | 1 |
| Hertig, A | 1 |
| Galstian, GM | 1 |
| Drokov, MIu | 1 |
| Katrysh, SA | 1 |
| Kliasova, GA | 1 |
| Giliazitdinova, EA | 1 |
| Karpova, TI | 1 |
| Marakusha, BI | 1 |
| Tartakovskiĭ, IS | 1 |
| Hibino, M | 1 |
| Hibi, M | 1 |
| Akazawa, K | 1 |
| Hikino, K | 1 |
| Oe, M | 1 |
| Ferrufino, E | 1 |
| Mejía, C | 1 |
| Ortiz de la Tabla, V | 1 |
| Chiner, E | 1 |
| Higa, F | 1 |
| Arakaki, N | 1 |
| Tateyama, M | 1 |
| Koide, M | 1 |
| Shinzato, T | 2 |
| Kawakami, K | 1 |
| Saito, A | 1 |
| Watson, AM | 1 |
| Boyce, TG | 1 |
| Wylam, ME | 1 |
| Dunbar, LM | 1 |
| Khashab, MM | 2 |
| Kahn, JB | 1 |
| Zadeikis, N | 2 |
| Xiang, JX | 1 |
| Tennenberg, AM | 2 |
| Yu, VL | 3 |
| Greenberg, RN | 1 |
| Stout, JE | 2 |
| Olson, WH | 1 |
| Mykietiuk, A | 1 |
| Fernández-Sabé, N | 1 |
| Dorca, J | 1 |
| Verdaguer, R | 2 |
| Manresa, F | 1 |
| Gudiol, F | 1 |
| Blázquez Garrido, RM | 1 |
| Espinosa Parra, FJ | 1 |
| Alemany Francés, L | 1 |
| Ramos Guevara, RM | 1 |
| Sánchez-Nieto, JM | 1 |
| Segovia Hernández, M | 1 |
| Serrano Martínez, JA | 1 |
| Huerta, FH | 1 |
| Kraus, CN | 1 |
| Zalkikar, J | 1 |
| Powers, JH | 1 |
| Lück, PC | 1 |
| Steinert, M | 1 |
| Pedro-Botet, L | 1 |
| Antonarakis, ES | 1 |
| Wung, PK | 1 |
| Durand, DJ | 1 |
| Leyngold, I | 1 |
| Meyerson, DA | 1 |
| Pedro-Botet, ML | 1 |
| García-Cruz, A | 1 |
| Tural, C | 1 |
| Mateu, L | 1 |
| Sopena, N | 1 |
| Roure, S | 1 |
| Rey-Joly, C | 1 |
| Sabria, M | 1 |
| Gudiol, C | 1 |
| Angeles Domínguez, M | 1 |
| Fernández-Sevilla, A | 1 |
| Baltch, AL | 2 |
| Smith, RP | 2 |
| Ritz, W | 1 |
| Salord, JM | 1 |
| Matsiota-Bernard, P | 1 |
| Staïkowsky, F | 1 |
| Kirstetter, M | 1 |
| Frottier, J | 1 |
| Nauciel, C | 1 |
| Bouhaja, B | 1 |
| Thabet, H | 1 |
| Slim, L | 1 |
| Aissa, F | 1 |
| Amamou, M | 1 |
| Yacoub, M | 1 |
| Edelstein, MA | 2 |
| Lehr, KH | 1 |
| Ren, J | 1 |
| Tsuji, H | 1 |
| Takazakura, E | 1 |
| Arnold, B | 1 |
| Brieland, JK | 1 |
| Loebenberg, D | 1 |
| Menzel, F | 1 |
| Hare, RS | 1 |
| Suzuki, K | 1 |
| Tachibana, A | 1 |
| Hatakeyama, S | 1 |
| Oka, T | 1 |
| Ritz, WJ | 1 |
| Franke, MA | 1 |
| Michelsen, PB | 1 |
| Doyle, E | 1 |
| Chidiac, C | 2 |
| Senneville, E | 2 |
| Mouton, Y | 2 |
| Peugeot, RL | 1 |
| Lipsky, BA | 1 |
| Hooton, TM | 1 |
| Pecoraro, RE | 1 |
| Leroy, O | 1 |
| Beuscart, C | 1 |
| Sivery, B | 1 |
| Vincent du Laurier, M | 1 |
| Fitzgeorge, RB | 1 |
| Featherstone, AS | 1 |
| Baskerville, A | 1 |
5 reviews available for ofloxacin and Infections, Legionella pneumophila
| Article | Year |
|---|---|
An update on Legionella.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Azithromycin; Community-Acquired Infections; Cross Infec | 2010 |
Relapsing Legionella pneumophila cellulitis: a case report and review of the literature.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Cellulitis; Fatal Outcome; Female; Humans; Immunocompromi | 2010 |
[Pathogenesis, diagnosis and therapy of Legionella infections].
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Antigens, Bacterial; Aza Compounds; Azithromycin; Cipr | 2006 |
Legionella: macrolides or quinolones?
Topics: Animals; Anti-Infective Agents; Azithromycin; Clinical Trials as Topic; Humans; Legionella pneumophi | 2006 |
[Value of quinolones in the treatment of lower respiratory tract infections caused by intracellular organisms, excluding mycobacteria].
Topics: Anti-Infective Agents; Chlamydia Infections; Ciprofloxacin; Enoxacin; Erythromycin; Humans; In Vitro | 1992 |
5 trials available for ofloxacin and Infections, Legionella pneumophila
| Article | Year |
|---|---|
Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
Topics: Adult; Anti-Bacterial Agents; Chlamydia Infections; Chlamydophila pneumoniae; Community-Acquired Inf | 2004 |
Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, Bacterial; Female; Humans; Legionnaires' Disease; Levo | 2005 |
Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides.
Topics: Anti-Bacterial Agents; Case-Control Studies; Disease Outbreaks; Drug Therapy, Combination; Female; H | 2005 |
Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin.
Topics: Adult; Aged; Bronchitis; Chlamydia Infections; Erythromycin; Female; Humans; Legionnaires' Disease; | 1991 |
[Treatment of pneumonia caused by Legionella, Mycoplasma, Chlamydiae and Rickettsia using ofloxacin].
Topics: Adult; Aged; Female; France; Humans; Legionnaires' Disease; Male; Middle Aged; Multicenter Studies a | 1989 |
28 other studies available for ofloxacin and Infections, Legionella pneumophila
| Article | Year |
|---|---|
[Therapeutic efficacy of levofloxacin against a model of replicable Legionella pneumophila lung infection in DBA/2 mice].
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Bacte | 2009 |
[Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
Topics: Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Cohort Studies; Co | 2010 |
Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Topics: Administration, Oral; Anti-Bacterial Agents; Azithromycin; Chi-Square Distribution; Clarithromycin; | 2010 |
Case of Legionella pneumonia complicated with pulmonary thromboembolism.
Topics: Anti-Bacterial Agents; Anticoagulants; Community-Acquired Infections; Heparin; Humans; Legionnaires' | 2010 |
In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bridged-Ring Compounds; Cell Line; Cells, Cultured; Cl | 2011 |
Ofloxacin: new applications for the prevention of urinary tract infections in renal graft recipients.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Drug Resistance, Bacterial; Dru | 2011 |
[A case of legionellesis pneumonia verified by isolation of Legionella pneumophila serogroup 1 from bronchoalveolar lavage fluid treated with levofloxacine and tigecycline].
Topics: Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Drug Therapy, Combination; Humans; Legionella p | 2011 |
[A case of Legionnaires' pneumonia accompanied by clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) with transient altered mental status and cerebellar symptoms, which responded to treatment by antibiotics and corticoste
Topics: Adrenal Cortex Hormones; Cerebellar Ataxia; Corpus Callosum; Encephalitis; Humans; Legionnaires' Dis | 2011 |
Empyema caused by Legionella pneumophila.
Topics: Acute-Phase Proteins; Aged; Antigens, Bacterial; beta-Lactams; Body Fluids; Cough; Drug Therapy, Com | 2012 |
In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Cell Line; Erythromycin; Fluoroquinolones; Guinea | 2003 |
Legionella pneumonia: infection during immunosuppressive therapy for idiopathic pulmonary hemosiderosis.
Topics: Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hemosiderosis; Humans; Immunosuppressiv | 2004 |
Levofloxacin efficacy in the treatment of community-acquired legionellosis.
Topics: Clinical Trials as Topic; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Admi | 2004 |
Levofloxacin and macrolides for treatment of Legionnaires disease: multiple comparisons give few answers.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Legionnaires' Di | 2005 |
An atypical complication of atypical pneumonia.
Topics: Anti-Bacterial Agents; Female; Humans; Legionella pneumophila; Legionnaires' Disease; Middle Aged; M | 2006 |
Severe Legionnaires' disease successfully treated with levofloxacin and azithromycin.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; Drug Therapy, Combinatio | 2006 |
Outbreak of Legionnaires' disease in immunosuppressed patients at a cancer centre: usefulness of universal urine antigen testing and early levofloxacin therapy.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Bacterial; Cancer Care Facilities; Cross Infection; Female | 2007 |
Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Drug Synergism; Drug Ther | 1995 |
Unsuccessful treatment of Legionella pneumophila infection with a fluoroquinolone.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Drug Therapy, Combination; Erythromyci | 1993 |
[Mixte community-acquired Legionella pneumophila and Staphylococcus aureus pneumonia].
Topics: Adult; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Legionnaires' Disea | 1993 |
In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia.
Topics: Animals; Anti-Infective Agents; Guinea Pigs; Humans; Legionella pneumophila; Legionnaires' Disease; | 1996 |
[Legionella pneumonia successfully treated despite late diagnosis].
Topics: Administration, Oral; Aged; Anti-Infective Agents; Cilastatin; Drug Combinations; Humans; Imipenem; | 1997 |
Legionnaires' disease.
Topics: Anti-Infective Agents; Azithromycin; Humans; Imipenem; Legionnaires' Disease; Ofloxacin | 1998 |
Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Erythromycin; HL-60 Cells; Humans; Legi | 1998 |
Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cortisone; Dis | 2000 |
[Fibrosing alveolitis following Legionella pneumonia].
Topics: Anti-Inflammatory Agents; Clarithromycin; Drug Therapy, Combination; Humans; Legionnaires' Disease; | 2000 |
Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila.
Topics: Anti-Bacterial Agents; Erythromycin; Humans; Ketolides; Legionella pneumophila; Legionnaires' Diseas | 2000 |
In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Azithromycin; Body Weight; Fluoroquinolones; Gemif | 2001 |
The effect of ofloxacin on the intracellular growth of Legionella pneumophila in guinea pig alveolar phagocytes.
Topics: Animals; Bronchoalveolar Lavage Fluid; Ciprofloxacin; Erythromycin; Guinea Pigs; Legionella; Legionn | 1988 |